BPG is committed to discovery and dissemination of knowledge
Minireviews
Copyright: ©Author(s) 2026.
World J Clin Oncol. Nov 24, 2026; 17(11): 126700
Published online Nov 24, 2026. doi: 10.5306/wjco.126700
Figure 1
Figure 1  Incremental correlation between number of lymph nodes removed (X-axis) and number of lymph metastatic nodes (Y-axis) from our institutional cohort of 589 patients.
Figure 2
Figure 2 Nodal stage migration in non-metastatic gastric cancer: Kaplan-Meier 10-year overall survival according to lymph node retrieval. A: 124 patients undergoing distal or total gastrectomy with fewer than 20 (distal) or 25 (total) lymph nodes examined (P < 0.001); B: 465 with more than 20 nodes retrieved after distal gastrectomy and 25 nodes after total, as recommended by Textbook Outcome in Gastric Surgery, (P < 0.001). Author’s data classified according to the 8th edition of the American Joint Committee on Cancer/Union for International Cancer Control tumor node metastasis classification.
Figure 3
Figure 3 Pathological views of gastric cancer. All images are self-generated. A: Microsatellite instable (MSI) MSH2 4 ×; B: MSI MSH6 4 ×; C: MSI MLH1 4 ×; D: MSI PMS2 4 ×; E: Programmed cell death ligand 1 (PD-L1) 4 ×; F: PD-L1 10 ×; G: PD-L1+ 20 ×; H: Epstein-Barr encoding region in situ hybridization (EBER ISH) 4 ×; I: EBER ISH 10 ×; J: EBER ISH 20 ×; K: Human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) 4 ×; L: HER2 IHC 10 ×; M: HER2 IHC 20 ×; N: Epithelial-mesenchymal transition (EMT) + CK8/18 4 ×; O: EMT+ E-cadherin 4 ×; P: EMT+ cluster of differentiation 44 4 ×; Q: EMT+ zinc finger E-box binding homeobox 1 10 ×.
Figure 4
Figure 4 Correlation between number of lymph nodes removed (X-axis) and metastatic (Y-axis). A: In 24 microsatellite instable; B: In 77 microsatellite stability cases. Red lines represent the median number of positive lymph nodes (3 in microsatellite instable and 5 in microsatellite stability). MSI: Microsatellite instable; MSS: Microsatellite stability.
Figure 5
Figure 5 Correlation between number of lymph nodes removed (X-axis) and metastatic (Y-axis). A: In 20 human epidermal growth factor receptor 2 (HER2) +; B: 92 HER2- cases. Red lines represent the median number of positive lymph nodes (2 in HER2+ and 4 in HER2-). HER2: Human epidermal growth factor receptor 2.
Figure 6
Figure 6 Multimodal treatment of locally advanced gastric cancer according to the molecular profiling. Extended lymphadenectomy contraindicated if para-aortic nodal involvement with bulky extragastric nodes or remaining stable after neoadjuvant chemotherapy. 1Indicate a possible role of immunotherapy in combination with chemotherapy in a neoadjuvant setting. MSI: Microsatellite instable; MSS: Microsatellite stability; EMT: Epithelial-mesenchymal transition; EBV: Epstein-Barr virus; PD-L1: Programmed cell death ligand 1; HER: Human epidermal growth factor receptor; HIPEC: Hyperthermic intraperitoneal chemotherapy.
Figure 7
Figure 7 Potential treatment of oligometastatic gastric cancer. HIPEC: Hyperthermic intraperitoneal chemotherapy; PIPAC: Pressurized intra-peritoneal aerosol chemotherapy.
Figure 8
Figure 8 Tissue sclerosis around major vessels after neoadjuvant chemotherapy. A and B: Own intraoperative frame; C: Schematic image. IVC: Inferior vein cava; Ao: Aorta; LRV: Left renal vein.


Write to the Help Desk